汉字News

← 汉字News
Chinese News for Learners
life
shēng huó
生活
·HSK 6

phase 3 (of a clinical trial)
sān qī
三期
clinical trial
línchuáng shìyàn
临床试验
to confirm / to prove
zhèngshí
证实
new type / novel
xīn xíng
新型
antihypertensive drug
jiàngyā yào
降压药
baxdrostat (drug name)
Bā shā sī tā
巴沙司他
therapeutic efficacy
liáoxiào
疗效
significant / marked
xiǎnzhù
显著

to publish
fābiǎo
发表
in / at (formal)
New England Journal of Medicine
Xīn Yīnggélán Yīxué Zázhì
新英格兰医学杂志
(relative clause marker)
de
phase 3
sān qī
三期
clinical trial
línchuáng shìyàn
临床试验
result
jiéguǒ
结果
to show / to indicate
xiǎnshì
显示
aldosterone synthase
quán gù tóng hé méi
醛固酮合酶
inhibitor
yìzhì jì
抑制剂
baxdrostat
Bā shā sī tā
巴沙司他
for / in terms of
duì
treatment-resistant
nán zhì xìng
难治性
hypertension / high blood pressure
gāo xuèyā
高血压
to have / to possess
jùyǒu
具有
significant / marked
xiǎnzhù
显著
therapeutic efficacy
liáoxiào
疗效
approximately
yuē
40 percent
40%
40%
(possessive particle)
de
medication-taking
yòng yào
用药
patient
huànzhě
患者
blood pressure
xuèyā
血压
to recover / to restore
huīfù
恢复
to / reaching (formal)
zhì
healthy
jiànkāng
健康
level
shuǐpíng
水平
US Food and Drug Administration
Měiguó Shípǐn Yàopǐn Jiāndū Guǎnlǐjú
美国食品药品监督管理局
already
to accept for review
shòulǐ
受理
its (formal)
priority review
yōuxiān shěnpíng
优先审评
application
shēnqǐng
申请
expected / anticipated
yùjì
预计
in (formal)
the year 2026
2026 nián
2026年
second quarter
dì èr jìdù
第二季度
to make (a decision)
zuòchū
作出
approval
shěnpī
审批
decision
juédìng
决定

April 4, 2026 at 2:00 PM

the latest issue
zuì xīn yī qī
最新一期
New England Journal of Medicine
Xīn Yīnggélán Yīxué Zázhì
新英格兰医学杂志
to publish / to release
fābù
发布
(completion particle)
le
one (study / item)
yī xiàng
一项
about / regarding
guānyú
关于
new type / novel
xīn xíng
新型
antihypertensive drug
jiàngyā yào
降压药
baxdrostat
Bā shā sī tā
巴沙司他
baxdrostat (antihypertensive drug)
baxdrostat
baxdrostat
(relative clause marker)
de
phase 3
sān qī
三期
clinical trial
línchuáng shìyàn
临床试验
result
jiéguǒ
结果
the said / this (formal)
gāi
trial / experiment
shìyàn
试验
in total
gòng
to enroll / to include
nàrù
纳入
794 people
794 míng
794名
treatment-resistant
nán zhì xìng
难治性
or
huò
uncontrolled
wèi kòngzhì
未控制
hypertension
gāo xuèyā
高血压
(possessive particle)
de
adult
chéngnián
成年
patient
huànzhě
患者
random / randomized
suíjī
随机
to divide into groups
fēn zǔ
分组
to receive
jiēshòu
接受
1 milligram
1 háokè
1毫克
2 milligrams
2 háokè
2毫克
dosage
jìliàng
剂量
(possessive particle)
de
baxdrostat
Bā shā sī tā
巴沙司他
or
huò
placebo
ānwèi jì
安慰剂
treatment
zhìliáo
治疗
course of treatment
liáochéng
疗程
12 weeks
shí èr zhōu
十二周
result
jiéguǒ
结果
to show / to indicate
xiǎnshì
显示
to take (medicine)
fúyòng
服用
1 milligram
1 háokè
1毫克
dosage
jìliàng
剂量
(possessive particle)
de
patient
huànzhě
患者
systolic blood pressure
shōusuō yā
收缩压
average / on average
píngjūn
平均
to decrease / to drop
xiàjiàng
下降
14.5 mmHg
14.5 háomǐ gǒngzhù
14.5毫米汞柱
to take (medicine)
fúyòng
服用
2 milligrams
2 háokè
2毫克
(possessive particle)
de
patient
huànzhě
患者
to decrease / to drop
xiàjiàng
下降
15.7 mmHg
15.7 háomǐ gǒngzhù
15.7毫米汞柱
both / all (formal)
jūn
significantly
xiǎnzhù
显著
superior to / better than
yōu yú
优于
placebo
ānwèi jì
安慰剂
group
(possessive particle)
de
5.8 mmHg
5.8 háomǐ gǒngzhù
5.8毫米汞柱
even more / particularly (formal)
gèng wéi
更为
key / critical
guānjiàn
关键
(possessive particle)
de
is
shì
approximately
yuē
40 percent
40%
40%
(possessive particle)
de
medication-taking
yòng yào
用药
patient
huànzhě
患者
blood pressure
xuèyā
血压
to recover / to restore
huīfù
恢复
to / reaching (formal)
zhì
healthy
jiànkāng
健康
level
shuǐpíng
水平
far / much
yuǎn
higher than
gāo yú
高于
placebo
ānwèi jì
安慰剂
group
less than / insufficient
bùzú
不足
20 percent
20%
20%
(possessive particle)
de
proportion / ratio
bǐlì
比例
baxdrostat
Bā shā sī tā
巴沙司他
is
shì
a type of
yī zhǒng
一种
aldosterone synthase
quán gù tóng hé méi
醛固酮合酶
inhibitor
yìzhì jì
抑制剂
through / by means of
tōngguò
通过
to inhibit / to suppress
yìzhì
抑制
adrenal gland
shèn shàng xiàn
肾上腺
to secrete
fēnmì
分泌
aldosterone
quán gù tóng
醛固酮
hormone
jīsù
激素
to (purpose marker)
lái
to lower / to reduce
jiàngdī
降低
blood pressure
xuèyā
血压
its (formal)
mechanism of action
zuòyòng jīzhì
作用机制
with / compared with
existing / current
xiàn yǒu
现有
first-line (treatment)
yī xiàn
一线
antihypertensive drug
jiàngyā yào
降压药
completely different / diametrically opposite
jié rán bù tóng
截然不同
researchers
yánjiū rényuán
研究人员
to point out
zhǐchū
指出
this (formal)
zhè yī
这一
drug target
bǎ diǎn
靶点
for / in terms of
duì
aldosterone
quán gù tóng
醛固酮
to secrete
fēnmì
分泌
excessive / too much
guò duō
过多
caused by (formal)
suǒ zhì
所致
hypertension
gāo xuèyā
高血压
patient
huànzhě
患者
particularly / especially (formal)
yóuwéi
尤为
effective
yǒuxiào
有效
while / and (formal)
ér
such type / this kind (formal)
cǐ lèi
此类
patient
huànzhě
患者
in / among
zài
treatment-resistant
nán zhì xìng
难治性
hypertension
gāo xuèyā
高血压
population / group
qúntǐ
群体
within / among
zhōng
to account for / to make up
zhàn
considerable / significant
xiāngdāng
相当
proportion
bǐlì
比例
in / regarding
zài
safety (as a quality)
ānquán xìng
安全性
aspect / regard
fāngmiàn
方面
a small number / minority
shǎoshù
少数
study participant / test subject
shòushì zhě
受试者
to develop / to experience
chūxiàn
出现
hyperkalemia (high blood potassium)
gāo jiǎ xuè zhèng
高钾血症
to need / must (formal)
in
zài
clinical
línchuáng
临床
practice / application
shíjiàn
实践
within
zhōng
to apply / to subject to (formal)
jiāyǐ
加以
monitoring / to monitor
jiāncè
监测
US Food and Drug Administration
Měiguó Shípǐn Yàopǐn Jiāndū Guǎnlǐjú
美国食品药品监督管理局
already
(action marker)
jiāng
the drug / this drug
gāi yào
该药
to include / to place on list
lièrù
列入
priority review
yōuxiān shěnpíng
优先审评
program / procedure
chéngxù
程序
target
mùbiāo
目标
approval
shěnpī
审批
date
rìqī
日期
set for / scheduled for
dìng yú
定于
the year 2026
2026 nián
2026年
second quarter
dì èr jìdù
第二季度
given that / in light of (formal)
jiànyú
鉴于
global
quánqiú
全球
hypertension
gāo xuèyā
高血压
patient
huànzhě
患者
total number
zǒngshù
总数
more than / exceeding (formal)
one billion people
shí yì rén
十亿人
among which / of which
qízhōng
其中
treatment-resistant
nán zhì xìng
难治性
case (medical)
bìnglì
病例
proportion
bǐlì
比例
considerable / significant
kěguān
可观
this (occasion / trial)
cǐ cì
此次
trial
shìyàn
试验
result
jiéguǒ
结果
(passive marker)
bèi
medical community / medical circles
yīxué jiè
医学界
to regard as / to consider as
shì wéi
视为
important / significant
zhòngyào
重要
breakthrough
tūpò
突破

New Words

jiàngyā yào
降压药
antihypertensive drug
línchuáng
临床
clinical
xuèyā
血压
blood pressure
huànzhě
患者
patient
yǒuxiào
有效
effective
zhìliáo
治疗
treatment
jīzhì
机制
mechanism
jīsù
激素
hormone
tūpò
突破
breakthrough
ānquán
安全
safe

News in English

Lifestyle & Culture

Phase 3 Trial Shows Baxdrostat Significantly Lowers Blood Pressure in Patients Resistant to Standard Treatment

A phase 3 clinical trial in the New England Journal of Medicine shows baxdrostat, an aldosterone synthase inhibitor, significantly lowers blood pressure in resistant hypertension patients, with around 40 percent reaching healthy levels.

The latest issue of the New England Journal of Medicine published the phase 3 clinical trial results for the new antihypertensive drug baxdrostat. The trial enrolled 794 patients with treatment-resistant or uncontrolled hypertension, randomly assigned to receive 1 milligram, 2 milligrams of baxdrostat, or placebo for a 12-week course. Results showed that patients taking 1 milligram had average systolic blood pressure decrease of 14.5 mmHg, and those taking 2 milligrams decreased 15.7 mmHg, both significantly better than the placebo group's 5.8 mmHg. Notably, approximately 40% of treated patients' blood pressure recovered to healthy levels, far exceeding the placebo group's less than 20% proportion. Baxdrostat is an aldosterone synthase inhibitor that lowers blood pressure by inhibiting adrenal secretion of the aldosterone hormone, with a mechanism completely different from existing first-line antihypertensive drugs. Researchers noted this target is particularly effective for patients whose hypertension is caused by excessive aldosterone secretion, a considerable proportion of the treatment-resistant hypertension population. Regarding safety, a small number of participants developed hyperkalemia, requiring clinical monitoring. The US FDA has placed the drug in priority review, with approval targeted for the second quarter of 2026. Given the global hypertension patient population exceeds one billion, with considerable treatment-resistant cases, these trial results are viewed by the medical community as an important breakthrough.

More in Lifestyle & Culture

England
Yīnggélán
英格兰
extra time / overtime
jiā shí sài
加时赛
to defeat / to beat
jī bài
击败
Norway
Nuówēi
挪威
to advance / to qualify for the next stage
jìnjí
晋级
the World Cup
shìjièbēi
世界杯
the semifinal
bànjuésài
半决赛

England Beat Norway 2-1 in Extra Time to Reach World Cup Semifinal

Argentina
Āgēntíng
阿根廷
by a score of / with
three to one (score)
3 bǐ 1
3比1
to eliminate / to knock out
táotài
淘汰
Switzerland
Ruìshì
瑞士
to advance / to progress to the next stage
jìnjí
晋级
the World Cup
shìjièbēi
世界杯
the top four / the semifinal stage
sìqiáng
四强

Argentina Beat Switzerland 3-1 to Reach World Cup Semifinal

Spain
Xībānyá
西班牙
2-1 (score)
liǎng bǐ yī
两比一
to eliminate / knock out
táotài
淘汰
Belgium
Bǐlìshí
比利时
to advance to the next round
jìnjí
晋级
World Cup
Shìjiè Bēi
世界杯
semifinal
bànjuésài
半决赛

Spain Beat Belgium 2-1 to Reach World Cup Semifinal

Congo
Gāngguǒ
刚果
Ebola
Āibólā
埃博拉
epidemic / outbreak
yìqíng
疫情
death toll
sǐwáng rénshù
死亡人数
to exceed / to surpass
tūpò
突破
600
liùbǎi
六百
virus
bìngdú
病毒
to spread to
mànyán zhì
蔓延至
new provinces
xīn shěngfèn
新省份

Congo Ebola Death Toll Tops 600 as Virus Spreads to New Provinces